Monoclonal antibodies and progressive multifocal leukoencephalopathy - Wikidata - awgldk - TriplyDB

Monoclonal antibodies and progressive multifocal leukoencephalopathy

Monoclonal antibodies and progressive multifocal leukoencephalopathy

http://www.wikidata.org/entity/Q28270413

about

Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps Functional protein microarray as molecular decathlete: a versatile player in clinical proteomics Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children The changing landscape of progressive multifocal leukoencephalopathy.Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.Recent developments in multiple sclerosis therapeutics Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.Eculizumab-related progressive multifocal leukoencephalopathy.Tolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients.Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.Frequency and large T (LT) sequence of JC polyomavirus DNA in oligodendrocytes, astrocytes and granular cells in non-PML brain.Rapid identification of monospecific monoclonal antibodies using a human proteome microarray.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Persistence and pathogenesis of the neurotropic polyomavirus JC The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology.Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents Characterization of monoclonal antibody's binding kinetics using oblique-incidence reflectivity difference approach Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation.Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.Pathogenesis of progressive multifocal leukoencephalopathy--revisited The link between VLA-4 and JC virus reactivation.CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflamm Targeting kinases for the treatment of inflammatory diseases.Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection.Specific and quantitative detection of Human polyomaviruses BKPyV and JCPyV in the healthy Pakistani population Juvenile idiopathic arthritis: management and therapeutic options.Role for tumor necrosis factor-α in JC virus reactivation and progressive multifocal leukoencephalopathy.Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.Progressive multifocal leukoencephalopathy masquerading as cerebellar infarction.JC polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen-sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab.Quantification of human and animal viruses to differentiate the origin of the fecal contamination present in environmental samples.Latent virus reactivation risk and biological drugs: chronic inflammatory and immune-mediated disorders.Editorial: leukocyte-targeting toxins as therapeutics in allergic asthma.Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate.Reactivation of human polyomavirus JC in patients affected by psoriasis vulgaris and psoriatic arthritis and treated with biological drugs: preliminary results.Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases.

P2860

Q26784434-ED73D46D-982F-497E-B9E8-D39B15F3D88F Q26823444-53E6B7AF-0A9C-46AA-AE12-E83E72FA3BF8 Q27025953-0E3BC477-EDAD-4D34-9FAA-615274A62C13 Q28538974-326098A3-E2B8-4F2E-85CE-2D1001876167 Q28575131-4F4B1D6F-2AFA-41EB-97AC-28284DAB9FE0 Q30403035-779A2737-D78D-43A6-A82B-9A932AEC56E1 Q30876283-18DCE1EF-578A-47EF-B762-8C0B9E3DFFF8 Q30962193-42A5752C-0CAF-4290-940A-EED30384A841 Q33401321-C76843BE-7EE1-4D61-AF6C-9D434CBC759A Q33428818-306CF46E-42AC-428A-9674-B7F35329D4C6 Q33571293-EE29C290-478F-4DB7-9CFF-85AB0A8B1EDC Q33980153-87A425B2-2266-4C44-812F-453B4E6F1DFE Q34032491-5580A7EA-CE55-4305-BC2D-F9C2CB5D0BD2 Q34151218-7652FC72-8D57-4F4B-9535-11CEDC6E3483 Q34212799-11116D2E-5E43-43A5-88D8-3E1BB09896B9 Q34459843-B2C51B11-D450-4A9F-80F9-136AB1C33292 Q34629128-C2E475D2-FC64-4B6A-9C7F-1B6BABE32BE0 Q35620090-3A5BAD0E-CFD4-4DC4-B796-99483877C9B2 Q36211543-086D94BC-893A-42E3-B822-24F2987BE5E0 Q36318597-728E83AC-9176-46D9-9BC0-3D8BF1DD04D3 Q37243068-D1E2E8B2-50C1-4759-B50D-1400F7C72C9E Q37814815-C74F19DF-D665-4BD5-A1A8-2FB037EB32A9 Q37828002-28E1B19F-4E84-4306-9786-53D00F84E758 Q37965603-0B32D15B-2334-42DD-A8C2-C7A03ADDB094 Q38025878-73ED0AC0-F766-468E-A1FE-50956799E544 Q38028572-543A5F56-90B8-4EC1-AD95-1E1B4E8BB532 Q38144256-3719D64D-1409-40A1-A02B-C90F7DD06F3E Q38822430-5F0DA758-A488-42A4-A679-40005260EC3D Q39243858-2D4A4542-28C9-4776-9836-49F888567B29 Q39615725-58E87AF0-5CC4-445B-9867-E903E83EBEA5 Q40039485-739468C4-2E35-4AC4-B04D-AB18E4C6FA04 Q40724070-ED212ED0-D4F0-4AF2-A585-1DBFA1D277DA Q40965913-46062EF1-3905-4E84-A481-1F710C152A2A Q41461627-22284CF9-67CC-4D66-A6EC-ED80CEDA4E1D Q42236159-44708445-EC35-40AF-8369-31B0F20D4208 Q42336260-7D010E48-5935-4106-B7FF-43FC5C73EB6B Q46120241-58292A2A-34D8-4ECA-A485-303CF4590DC3 Q46437505-A0899BC5-E5DA-4E36-BEB9-7DBEA27083D7 Q52708818-82CF6FC4-F38A-4AF7-A6F2-6660BCE2B91D

P2860

Monoclonal antibodies and progressive multifocal leukoencephalopathy

http://www.wikidata.org/entity/Q28270413

description

2009 nî lūn-bûn

@nan

2009 թուականին հրատարակուած գիտական յօդուած

@hyw

2009 թվականին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@ast

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@en

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@nl

type

label

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@ast

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@en

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@nl

prefLabel

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@ast

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@en

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@nl

P1433

Q28270413-A81D5D0F-1868-4333-B0D9-B39B07B6FCC2

P1476

Q28270413-58A1C926-CC07-418F-B3D6-73269B985922

P2093

Q28270413-49D6B6BB-3D54-4F77-AAA0-20C0AACBA846

Q28270413-594FF3B4-5577-4CDF-ACDB-0DE705E3450D

Q28270413-F159FB49-7163-4B10-AC67-4E81AF53077E

P2860

Q28270413-0501F1CE-A7CC-42E5-A00C-AB20339B227A

Q28270413-0988CA7C-B228-43C9-88FF-397F684BBB7E

Q28270413-0BC8E1B1-2840-424E-9D65-F1187648966B

Q28270413-0DB8A138-DDB6-4BBC-A7A8-B1C62727BB38

Q28270413-1927117F-7BC2-4005-BBD6-5707F4BDA23D

Q28270413-1C590DE5-1D02-4AD6-B43E-76E3F64F2E20

Q28270413-2F4719D8-1BA3-4938-B4B7-02631632F7AF

Q28270413-4896CFAF-993A-456B-81F2-79458AC80383

Q28270413-4EDFB234-D49F-4C91-9F75-DF6037601BAE

Q28270413-50E73B88-B820-4687-A72F-83545DE95F4A

P304

Q28270413-AF31238D-B57F-41B7-B09A-1C18600FE872

P31

Q28270413-D2B47C3D-7AB1-4AB5-8C08-B278D0FEEBF4

P3181

Q28270413-EC395FAF-07F8-4F7B-89C5-58B7643E8A10

P356

Q28270413-8A96C96B-2139-42F1-9261-5D8F921D6537

P407

Q28270413-D951C516-52CF-4923-82BE-2861031985F2

P433

Q28270413-92C96A44-E7BE-402C-A2EE-05584D87AF96

P478

Q28270413-8E5121F3-1C91-41D5-89C1-1F16DFBFBF7D

P577

Q28270413-EE12E2C2-1CE6-45D0-8026-8042C0D68298

P5875

Q28270413-82A5E25B-A781-4BFD-A480-2A2F58A101EE

P698

Q28270413-BC262B58-606A-4B8B-9EEF-8080508D90FE

P921

Q28270413-088581D2-E561-47AD-8D5A-7D232E40C297

Q28270413-815FD434-DA59-4E84-BF5F-FDAE2B7B53FF

P932

Q28270413-D33E5F50-B99F-47D5-A323-52F4FE22B0DB

P3181

P356

P1433

Monoclonal Antibodies

P1476

Monoclonal antibodies and progressive multifocal leukoencephalopathy

@en

P2093

Eugene O Major

http://www.w3.org/2001/XMLSchema#string

Joseph R Berger

http://www.w3.org/2001/XMLSchema#string

Sidney A Houff

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions.

The changing pattern of HIV neuropathology in the HAART era.

Opportunistic infections of the CNS in patients with AIDS: diagnosis and management.

Progressive multifocal leukoencephalopathy in patients with HIV infection.

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

P304

583-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3879191

http://www.w3.org/2001/XMLSchema#string

P356

10.4161/MABS.1.6.9884

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41026595

http://www.w3.org/2001/XMLSchema#string

P698

20073129

http://www.w3.org/2001/XMLSchema#string

P921

progressive multifocal leukoencephalopathy

P932

2791316

http://www.w3.org/2001/XMLSchema#string